Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Becton Dickinson and Company BDX, popularly known as BD, is scheduled to report second-quarter fiscal 2025 results on May 1, ...

Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

Stephen “Buck” Daniel said his client, retired truck driver Gary Walker, developed non-Hodgkin lymphoma and went through 10 cycles of chemotherapy and a stem cell transplant because of his “massive” ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE:BDX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

Choice Dekho proudly announces the launch of its live SAP IBP Demand Planning training sessions, conducted by seasoned ...

The stock's rise snapped a four-day losing streak.